Scadenza: 21 September 2021
Topic:
the proposed research is expected to deliver on several of the following outcomes:
-Significantly advance the molecular and neurobiological understanding of how genetic, epigenetic and environmental risk and resilience factors (such as psychosocial experiences, diet, sleep, natural and artificial light, use or abuse of drugs, infections and other exposures) interact to drive or prevent the transition from mental health to mental illness throughout the life course as well as how such molecular and neurobiological changes could be reversed. The use of computational modelling and/or artificial intelligence tools is encouraged for the analysis of big, complex and heterogeneous data.
-Develop relevant predictive models through federated analysis of large European cohorts of psychiatric disorders and investigate the biological and neural basis of pathogenetic mechanisms and symptoms shared by different disorders. If relevant to the disorders studied, develop neurobiologically-grounded models of cognition and social behaviour and apply these models and their simulation potential to the understanding and improved management of mental health conditions associated with behavioural or emotional dysfunction.
-Identify, validate and document different types or combinations of biomarkers for all of the following purposes:
development of robust quantitative, clinical measures of mental health;
identification of signatures, for example genetic and epigenetic blueprints, conferring susceptibility to and protection against mental illnesses;
establishment of more objective diagnostic and monitoring criteria (complementing current symptom-based criteria) to improve patient outcomes and reduce the stigma associated with mental illness;
prediction of treatment response and risk of relapse for better, more scientifically-guided and targeted use of currently available preventive and therapeutic interventions for different population groups.
For biomarker discovery, applicants are encouraged to take stock of advances in disciplines such as for instance neuropsychology, neurophysiology, neuroendocrinology, neuroimaging, electrophysiological monitoring, e-health/m-health, -omics (genomics, epigenomics, transcriptomics, proteomics, metabolomics, lipidomics, exposomics, microbiomics including the role of the microbiota-gut-brain axis), optogenetics, nanomedicine, stem cell biology, neuroimmunology and immunopsychiatry.
Discover new disease pathways and drug targets (including pathways involved in maintaining mental health) to boost the development of new (or repurposed) classes of safer and more effective medications[3] for the prevention and treatment of mental illnesses (including relapse prevention).
Establish the molecular and neurobiological effects as well as cognitive and psychological consequences of both pharmacological and non-pharmacological prevention strategies (for example: neurostimulation, neurofeedback, psychotherapy and other psychological/behavioural interventions, light therapy, diet, exercise, lifestyle, mindfulness or a combination of them) and assess their efficacy and side effects as part of clinical trials (also determining windows of opportunity when preventive actions are most effective throughout the life course).
Proposals may cover different stages in the continuum of the innovation cycle (from basic and translational research to the validation of findings in real-world settings) and should ensure strong involvement of end-users, including citizens and patients. Sex and gender differences and the effects of age should be duly taken into account. International cooperation is encouraged and the proposed research is expected to be multidisciplinary, including through the involvement of medical sciences, psychological sciences, social sciences and the humanities
Programma:
HORIZON-RIA HORIZON Research and Innovation Actions
Ente finanziatore:
EU
Budget complessivo:
60 milion
Who can participate:
To be eligible for funding, applicants must be established in one of the eligible countries, i.e.:
– the Member States of the European Union, including their outermost regions;
– the Overseas Countries and Territories (OCTs) linked to the Member States;
– eligible non-EU countries:
- countries associated to Horizon Europe;
- low- and middle-income countries
Partnership: Mandatory
Status:
Closed
Quota finanziabile:
100%
Topic:
the proposed research is expected to deliver on several of the following outcomes:
-Significantly advance the molecular and neurobiological understanding of how genetic, epigenetic and environmental risk and resilience factors (such as psychosocial experiences, diet, sleep, natural and artificial light, use or abuse of drugs, infections and other exposures) interact to drive or prevent the transition from mental health to mental illness throughout the life course as well as how such molecular and neurobiological changes could be reversed. The use of computational modelling and/or artificial intelligence tools is encouraged for the analysis of big, complex and heterogeneous data.
-Develop relevant predictive models through federated analysis of large European cohorts of psychiatric disorders and investigate the biological and neural basis of pathogenetic mechanisms and symptoms shared by different disorders. If relevant to the disorders studied, develop neurobiologically-grounded models of cognition and social behaviour and apply these models and their simulation potential to the understanding and improved management of mental health conditions associated with behavioural or emotional dysfunction.
-Identify, validate and document different types or combinations of biomarkers for all of the following purposes:
development of robust quantitative, clinical measures of mental health;
identification of signatures, for example genetic and epigenetic blueprints, conferring susceptibility to and protection against mental illnesses;
establishment of more objective diagnostic and monitoring criteria (complementing current symptom-based criteria) to improve patient outcomes and reduce the stigma associated with mental illness;
prediction of treatment response and risk of relapse for better, more scientifically-guided and targeted use of currently available preventive and therapeutic interventions for different population groups.
For biomarker discovery, applicants are encouraged to take stock of advances in disciplines such as for instance neuropsychology, neurophysiology, neuroendocrinology, neuroimaging, electrophysiological monitoring, e-health/m-health, -omics (genomics, epigenomics, transcriptomics, proteomics, metabolomics, lipidomics, exposomics, microbiomics including the role of the microbiota-gut-brain axis), optogenetics, nanomedicine, stem cell biology, neuroimmunology and immunopsychiatry.
Discover new disease pathways and drug targets (including pathways involved in maintaining mental health) to boost the development of new (or repurposed) classes of safer and more effective medications[3] for the prevention and treatment of mental illnesses (including relapse prevention).
Establish the molecular and neurobiological effects as well as cognitive and psychological consequences of both pharmacological and non-pharmacological prevention strategies (for example: neurostimulation, neurofeedback, psychotherapy and other psychological/behavioural interventions, light therapy, diet, exercise, lifestyle, mindfulness or a combination of them) and assess their efficacy and side effects as part of clinical trials (also determining windows of opportunity when preventive actions are most effective throughout the life course).
Proposals may cover different stages in the continuum of the innovation cycle (from basic and translational research to the validation of findings in real-world settings) and should ensure strong involvement of end-users, including citizens and patients. Sex and gender differences and the effects of age should be duly taken into account. International cooperation is encouraged and the proposed research is expected to be multidisciplinary, including through the involvement of medical sciences, psychological sciences, social sciences and the humanities
Who can participate:
To be eligible for funding, applicants must be established in one of the eligible countries, i.e.:
– the Member States of the European Union, including their outermost regions;
– the Overseas Countries and Territories (OCTs) linked to the Member States;
– eligible non-EU countries:
- countries associated to Horizon Europe;
- low- and middle-income countries
Programme:
HORIZON-RIA HORIZON Research and Innovation Actions
Consortium: Required
Status: Open
Total budget:
60 milion
Funding rate:
100%
Notes:
The Commission estimates that an EU contribution of around EUR 10.00 million would allow these outcomes to be addressed appropriately.
